Common bile duct neoplasm

Summary

Common bile duct neoplasm (MONDO:0006709) is a cancer and 6 clinical trials. Top therapeutic interventions include dexamethasone. A subtype of common bile duct disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	common bile duct neoplasm
Mondo ID	MONDO:0006709
MeSH	D003138
DOID	DOID:4608
SNOMED CT	126857009
UMLS	C0009442
MedGen	3178
Anatomy (UBERON)	UBERON:0001174
Is cancer (heuristic)	yes

Also known as: common bile duct neoplasm (disease) · common bile duct tumor · common bile duct tumour · neoplasm of common bile duct · tumor of common bile duct · tumour of common bile duct

Disease family

This is a subtype of common bile duct disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › common bile duct disorder › common bile duct neoplasm

Related subtypes (2): biliary dyskinesia, choledocholithiasis

Subtypes (1): ampulla of vater neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07161869	Not specified	NOT_YET_RECRUITING	Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)
NCT01683240	Not specified	COMPLETED	Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones
NCT02575014	Not specified	UNKNOWN	Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy
NCT05147389	Not specified	COMPLETED	Artificial Intelligence for Digital Cholangioscopy Neoplasia Diagnosis
NCT05678218	Not specified	COMPLETED	Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
NCT05945797	Not specified	COMPLETED	Effects of Dexamethasone on Common Bile Duct Cannulation Time

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXAMETHASONE	4	1